Despair of repair: Intravenous immunoglobulins in multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 72, Issue 1, 2002, Pages 1-4

  Stangel, M ^a   Hartung, H P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MYELIN PROTEIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; EDITORIAL; HUMAN; IMMUNOMODULATION; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMYELINIZATION; TREATMENT OUTCOME; ANIMAL; METABOLISM; PASSIVE IMMUNIZATION;

ANIMALS; CLINICAL TRIALS; HUMANS; IMMUNIZATION, PASSIVE; MULTIPLE SCLEROSIS; MYELIN PROTEINS; OLIGODENDROGLIA; TREATMENT OUTCOME;

EID: 0036364953     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.72.1.1     Document Type: Editorial

References (31)

1. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
2. Recommendations for off-label use of intravenously administered immunoglobulin preparations
3. Intravenous immunoglobulin treatment in neurological diseases
4. Therapie der multiplen sklerose mit immunglobulin G
5. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients
6. Gammaglobulintherapie be multipler sklerose (MS)
7. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
8. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
9. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses
10. Escolating immunotherapy of multiple sclerosis
11. Immunoglobulins promote remyelination in the central nervous system
12. Do antibodies stimulate myelin repair in multiple sclerosis?
13. Targeting of IgMk antibodies to oligodendrocytes promotes CNS remyelinotion
14. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis
15. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination
16. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis
17. IVIg treatment in multiple sclerosis: Pilot study results and design of a placebo-controlled, double-blind clinical trial
18. IV immunoglobulin does not reverse established weakness in MS. A double-blind, placebo-controlled trial
19. A placebo-controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis
20. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
21. Mechanisms of action of intravenous immune globulin in immune-mediated diseases
22. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases
23. Mechanism of action of intravenous immunoglobulin therapeutic considerations in the treatment of autoimmune neurologic diseases
24. Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes
25. Oligodendroglia are protected from antibody mediated complement injury by normal immunoglobulins (IVIg)
26. Normal polyclonal immunoglobulins (IVIg) inhibit microglial phagocytosis in vitro
27. Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors
28. Axonal transection in the lesions of multiple sclerosis
29. Side effects of high dose intravenous immunoglobulins
30. Adverse effects of intravenous immunoglobulin therapy
31. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood